Inside Japan’s Tooth Regrowth Human Trials: The Complete Timeline
An objective look at Toregem Biopharma's TRG-035 clinical trials at Kyoto University Hospital, current milestones, and what the data actually says.
The global conversation surrounding biological dental regeneration has shifted from theoretical laboratory experiments to concrete clinical execution in Japan. Spearheaded by Toregem Biopharma in conjunction with research teams at Kyoto University Hospital, human testing of the world's first "teething medicine" has marked a monumental shift in modern medicine.
Phase I: Safety and Molar Validation
The initial human safety trials (Phase I) kicked off in late 2024 and concluded operational enrollment phases through 2025. This randomized, placebo-controlled trial enrolled 30 healthy adult male participants aged 30 to 64 who were missing at least one molar.
Because the primary endpoint of Phase I was safety and systemic tolerance rather than large-scale tooth generation, the focus centered entirely on tracking how the human body reacts to the TRG-035 antibody. According to corporate disclosures, the trial confirmed a favorable safety profile with no serious adverse side effects reported.
Key Distinction: Congenital vs. Acquired Tooth Loss
A critical point often missed by mainstream media headlines is patient eligibility. While adult trials tested safety on missing molars, the active therapeutic focus moving into Phase II centers heavily on severe congenital anodontia (hypodontia)—children born missing six or more permanent teeth due to genetic factors. Treating age-related or decay-induced tooth loss in adults remains a secondary, longer-term horizon goal.
Phase IIa: Moving to Pediatric Patients
In mid-2026, Toregem Biopharma announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) completed its formal review of the clinical trial notification for a Phase IIa study.
This upcoming multi-center, open-label trial is designed to test dosing and efficacy in 24 children suffering from severe congenital tooth agenesis. Backed by an additional $5.3 million financing round (bringing total cumulative funding past $29 million), the company is actively preparing institutional review board assessments to guide the next generation of patients toward natural dental development.
The Road to 2030 and Beyond
While commercial availability for congenital applications is targeted tentatively around 2030, the broader market for adult restorative care remains dependent on subsequent clinical expansions. Analysts emphasize that while the science is authentic and rigorously backed by peer-reviewed animal trials in mice, ferrets, and dogs, consumers must maintain realistic expectations: this is an evolving biological frontier, not an over-the-counter remedy available today.